REVIEW

Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor–methotrexate combination therapy versus triple therapy in rheumatoid arthritis

Roy Fleischmann,1 Vanita Tongbram,2 Ronald van Vollenhoven,3 Derek H Tang,4,5 James Chung,4 David Collier,4 Shilpa Urs,2,6 Kerigo Ndirangu,2 George Wells,7 Janet Pope8

ABSTRACT

Objective: Clinical trials have not consistently demonstrated differences between tumour necrosis factor inhibitor (TNFi) plus methotrexate and triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in rheumatoid arthritis (RA). The study objective was to estimate the efficacy, radiographic benefits, safety and patient-reported outcomes of TNFi–methotrexate versus triple therapy in patients with RA.

Methods: A systematic review and network meta-analysis (NMA) of randomised controlled trials of TNFi–methotrexate or triple therapy as one of the treatment arms in patients with an inadequate response to or who were naive to methotrexate was conducted. American College of Rheumatology 70% response criteria (ACR70) at 6 months was the prespecified primary endpoint to evaluate depth of response. Data from direct and indirect comparisons between TNFi–methotrexate and triple therapy were pooled and quantitatively analysed using fixed-effects and random-effects Bayesian models.

Results: We analysed 33 studies in patients with inadequate response to methotrexate and 19 in patients naive to methotrexate. In inadequate responders, triple therapy was associated with lower odds of achieving ACR70 at 6 months compared with TNFi–methotrexate (OR 0.35, 95% credible interval (CrI) 0.19 to 0.64). Most secondary endpoints tended to favour TNFi–methotrexate in terms of OR direction; however, no clear increased likelihood of achieving these endpoints was observed for either therapy. The odds of infection were lower with triple therapy than with TNFi–methotrexate (OR 0.08, 95% CrI 0.00 to 0.57). There were no differences observed between the two regimens in patients naive to methotrexate.

Conclusions: In this NMA, triple therapy was associated with 65% lower odds of achieving ACR70 at 6 months compared with TNFi–methotrexate in patients with inadequate response to methotrexate. Although secondary endpoints numerically favoured TNFi–methotrexate, no clear differences were observed. The odds of infection were greater with TNFi–methotrexate. No differences were observed for patients naive to methotrexate. These results may help inform care of patients who fail methotrexate first-line therapy.

Key messages

What is already known about this subject?

▸ Previous studies have reported that tumour necrosis factor inhibitor (TNFi)–methotrexate and triple therapy (methotrexate/hydroxychloroquine/sulfasalazine) are equivalent in patients with rheumatoid arthritis (RA); however, many of these studies were not adequately powered while also suggesting deeper responses associated with TNFi–methotrexate.

What does this study add?

▸ In this network meta-analysis, American College of Rheumatology 70% response criteria (ACR70) at 6 months (primary endpoint) was more likely with TNFi–methotrexate versus triple therapy in patients with an adequate response to methotrexate. Other endpoints did not favour either therapy, although the calculated ORs favoured TNFi–methotrexate in their directionality.

How might this impact on clinical practice?

▸ The greater depth of response suggested by TNFi–methotrexate compared with triple therapy may inform therapy in patients with RA who failed previous methotrexate therapy.
INTRODUCTION
The current treatment paradigm for patients with rheumatoid arthritis (RA) consists of disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs (csDMARDs) and biologic DMARDs (bDMARDs). The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) propose methotrexate as the first step in the treatment of patients with active RA.\(^1\)\(^2\) Although ~30% of patients achieve full clinical remission with methotrexate monotherapy, 70% require a step-up treatment that includes the addition of either csDMARDs or bDMARDs.\(^3\) Several studies have suggested that initial combination therapy is superior to initial methotrexate monotherapy, whether this is a combination of csDMARDs or the combination of methotrexate with a tumour necrosis factor inhibitor (TNFi).\(^4\)-\(^12\) In patients with inadequate response to methotrexate, the addition of another agent(s) can lead to improved outcomes. Adding a TNFi was superior to adding placebo to methotrexate monotherapy;\(^13\) similarly, it has been shown that csDMARD triple therapy (adding hydroxychloroquine and sulfasalazine to methotrexate) is superior to methotrexate monotherapy.\(^14\) However, it is uncertain whether methotrexate plus TNFi is superior to a combination of csDMARDs or vs. vice versa. Using a completers analysis, the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial concluded that there was no difference between triple therapy and TNFi (specifically, etanercept) plus methotrexate for the endpoints ACR 20% response criteria (ACR20), ACR50, or Disease Activity Score including 28-joint count (DAS28; the primary endpoint) at weeks 48 and 102 in a population of patients who were mostly methotrexate-naive.\(^5\) However, there were differences favouring etanercept–methotrexate in several endpoints—radiographic progression and the percentage of patients achieving ACR70—suggesting that etanercept plus methotrexate was more effective than triple therapy in achieving clinically relevant outcomes over time.\(^7\) In the TEAR trial, more patients dropped out than the 10% expected (33% by week 48 and 37% by week 102); it is therefore possible that true differences between the two treatments were missed at weeks 48 and 102 because of inadequate power.\(^5\) Two randomised controlled trials (RCTs) compared triple therapy to TNFi–methotrexate as second-line therapy. In the Swefot trial in patients with early RA, TNFi–methotrexate was found initially to be superior to triple therapy in patients for whom methotrexate monotherapy had failed, but by year 2 this difference was no longer significant. This study had lower enrolment than originally planned, and a type 2 error at year 2 could not be excluded.\(^3\)\(^15\) Similar results were reported from the Rheumatoid Arthritis Comparison of Active Therapies (RACAT) trial, which also did not reach its target sample size for the primary endpoint of a 0.3-unit difference in DAS28 at week 48.\(^16\)

Network meta-analysis (NMA) is a model that allows indirect comparisons of interventions through the use of a network of interventions and comparisons.\(^17\) NMA can provide estimates of relative efficacy between all interventions connected through the network of trials, even those that have never been compared directly.\(^17\)-\(^19\) Thus, through combining direct and indirect evidence, NMA provide estimates and more power to determine between-group differences relative to single clinical trials or classical pair-wise meta-analyses.\(^20\) The objective of this NMA was to evaluate the clinical efficacy, radiographic outcomes, patient-reported outcomes (PROs) and safety of TNFi–methotrexate combination therapy compared with triple therapy in patients with active RA who were methotrexate-naive or had an inadequate response to methotrexate. As ACR and EULAR guidelines recommend methotrexate as first-line therapy in RA, the results in patients with inadequate response to methotrexate are likely more clinically relevant.

METHODS
Design
We conducted a systematic literature review of EMBASE, MEDLINE and the Cochrane library, followed by an NMA. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in the development and reporting of this analysis,\(^21\) which can be found in the online supplementary appendix.

Search strategy
The search strategy combined indexed and free-text terms for disease and interventions of interest and used the Scottish Intercollegiate Guidelines Network (SIGN) filter for RCTs in EMBASE and MEDLINE. No study filter was used in the Cochrane (Central Register of Controlled Trials (CENTRAL)) Library search. The three databases were searched through Ovid. The list of search terms can be found in the online supplementary material methods. Separate reproducible searches were conducted and were supplemented by a manual bibliography check of identified relevant review articles (including previously published systematic reviews and Cochrane reviews), and conference abstracts search in two professional conferences for 2012, 2013 and 2014. Conference abstracts were searched to complement data unavailable in the corresponding full-text publications. Studies available only as a conference meeting abstract were not included.

Eligibility criteria
Included studies were full-text manuscripts of RCTs conducted in adult patients with RA, stratified by methotrexate experience (inadequate responders vs naïve). Patients were treated with either TNFi–methotrexate combination therapy or triple therapy (methotrexate + hydroxychloroquine + sulfasalazine). TNFIs included in the analysis were adalimumab, certolizumab pegol,
Fleischmann R, et al. RMD Open 2017;3:e000371. doi:10.1136/rmdopen-2016-000371

etanercept, golimumab, infliximab and biosimilar infliximab. Studies reported at least one endpoint of clinical efficacy, radiographic progression, PRO or safety at 13 weeks, 26 weeks, 1 year or 2 years of follow-up (full list in online supplementary table S1).

Study identification and data extraction

Abstracts and full-text articles were screened by two reviewers, and data were extracted by one reviewer and validated by a second independent reviewer. Any uncertainties were resolved by a third reviewer.

Endpoints

As both treatment combinations have been shown to be effective in the treatment of RA, the prespecified primary endpoint of this analysis was ACR70 at 6 months in order to compare the depth of response of each of these regimes; other endpoints and time points analysed are listed in Table 1. The ACR responses were analysed at 3 months, 6 months, 1 year and 2 years.

Table 1 Endpoints analysed in the network meta-analysis

| Endpoints analysed | Time points analysed (all endpoints) |
|--------------------|-------------------------------------|
| Primary endpoint   |                                     |
| ACR70 at 6 months  | 3 months                            |
| Secondary endpoints|                                     |
| ACR50              | 6 months                            |
| ACR20              | 1 year                              |
| EULAR good response| 2 years                             |
| EULAR good/moderate response |          |
| DAS28-ESR          |                                     |
| DAS28-CRP          |                                     |
| DAS28-ESR/CRP LDA  |                                     |
| Change in DAS28-ESR|                                     |
| Change in DAS28-ESR|                                     |
| No radiographic progression |              |
| mTSS               |                                     |
| Change in joint erosion |                      |
| Change in joint space narrowing |                |
| Safety              |                                     |
| Overall AEs        |                                     |
| Dropout due to AEs |                                     |
| Overall infection  |                                     |
| Overall serious AEs|                                     |
| Malignancy         |                                     |
| Patient-reported outcomes |                    |
| Change in HAQ-DI   |                                     |
| Change in patient global assessment |           |
| Change in pain score|                                    |

ACR70/50/20, American College of Rheumatology 70%/50%/20% response criteria; AE, adverse event; CRP, C-reactive protein; DAS28, Disease Activity Score including 28-joint count; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire-Disability Index; LDA, low disease activity; mTSS, modified total Sharp score; RA, rheumatoid arthritis.

Assessment of bias

The quality of each study was assessed using the Cochrane Collaboration’s tool for assessing risk of bias for RCTs (see online supplementary table S2).22 We did not assess publication bias; however, all studies that met the eligibility criteria were included in the analysis.

Network meta-analysis

For all studies, the feasibility of an NMA was assessed by the academic authors who examined box plots of clinically important baseline characteristic distributions to explore the level of heterogeneity among treatment groups. Accordingly, the following assumptions were made: the sets of trials do not differ with respect to the distribution of effect modifiers, all doses of methotrexate are equivalent and the various TNFis identified were considered as one type of therapy.

The analysis was conducted using WinBUGS V 1.4.3 (MRC Biostatistics, Cambridge Institute of Public Health, Cambridge, UK). Vague (‘flat’) distributions were used such that any parameter value was equally likely. This approach assigns more weight in assuming the therapies are equivalent compared with applying informed prior or traditional frequentist approaches. Fixed-effects and random-effects models were run for each network of evidence and fitted with preferred model fit determined by the deviance information criterion (DIC). A model with a lower DIC score was considered a better fit. Both models were run for 3 months (13 weeks), 6 months (26 weeks), 1 year and 2 years. To evaluate simulation convergence, history, trace plots and Brooks-Gelman-Rubin statistics diagnostics were examined. Three chains were run each with 40 000 iterations and the traces were visually inspected.

For dichotomous endpoints, a logit model was used to estimate the odds of attaining an endpoint. ORs and 95% credible intervals (CrIs) of triple therapy versus TNFi–methotrexate were calculated, with ORs <1 indicating a better performance for TNFi–methotrexate for clinical efficacy and radiographic outcomes, and ORs >1 indicating a better performance for TNFi–methotrexate for safety outcomes. For continuous endpoints, a weighted mean difference between mean changes from baseline for treatments at follow-up was estimated using end-of-trial mean scores or change in mean score from baseline. Values >0 for difference in mean change from baseline of triple therapy versus TNFi–methotrexate indicated better performance for TNFi–methotrexate.

Handling of missing data was conducted according to the Cochrane Handbook for Systematic Reviews.23 When an endpoint of interest was not reported adequately or not in a format we could incorporate, attempts to inform missing data were undertaken, including contacting the authors of the study and cross-checking against previously published NMAs reporting the data point of
interest. We used the best available data from the specific time points indicated (ie, the Ns were not inflated to the number of randomised patients). We used the intent-to-treat method (with various imputation methods) as much as possible; for studies using completer-only or modified intent-to-treat methods, those data were used for the analysis. For studies missing SDs, an average of the SDs of all other studies in the same network was used for a particular study. Randomised arms with more than 20% crossover at any time point were not analysed beyond the time point where crossover occurred because treatment effects could not be attributed to the initial therapy once these crossovers took place.

Sensitivity analyses using non-responder imputation and completers data were compared with the main results of the study to determine whether the method used to account for missing data affected the results. Comparison between the results from the NMA and a classical pair-wise direct comparison were used to determine consistency.

RESULTS
Studies identified

The search yielded 6560 abstracts and citations from EMBASE, MEDLINE, and the Cochrane (CENTRAL) library. After screening, 60 full-text primary studies were identified for possible inclusion, which corresponded to 136 records. Of the 60 studies, 3932 4 were in patients with inadequate response to methotrexate, and 21 5 7 11 14 62-77 were in methotrexate-naive patients. A PRISMA diagram documenting the search, screening and trial selection process, and reasons for exclusion is shown in figure 1.21

Characteristics of studies

Patients with inadequate response to methotrexate

Inadequate response to methotrexate was defined as the presence of active RA despite current use of methotrexate; however, we observed differences in definitions across the studies. The descriptions of patients included the following: patients with active RA on methotrexate before the study, patients on stable doses of methotrexate for at least 4 weeks before study enrolment, patients who had active RA despite methotrexate treatment and patients with inadequate response to methotrexate treatment. Study and baseline characteristics of the studies are listed in online supplementary table S3. The baseline mean age was 37–61 years. Female enrolment ranged from 43% to 100%; the proportion of patients who were rheumatoid factor–positive (RF+) was 61–100%; and mean disease duration was 1.3–14.3 years. Baseline DAS28–erythrocyte sedimentation rate (ESR) ranged from 4.6 to 6.9 and DAS28–C-reactive protein (CRP) from 4.3 to 6.0. Our feasibility assessments of box plots of baseline characteristics across studies (see online supplementary figures S1–S14) determined that there were no clinically meaningful differences in treatment cohorts across the studies.

Methotrexate-naive patients

The definition of patients who were naive to methotrexate differed across the trials. In most cases, the definition was no prior exposure to methotrexate; however, a few studies allowed limited exposure to methotrexate. Also included was a study enrolling patients who had not received methotrexate within 6 months before randomisation as well as a single study that allowed ≤40 mg of total methotrexate in <20% of patients before the study period.6 Another study allowed patients with DMARD treatment, but only 10% of patients had received methotrexate before; therefore, it was included in this group of methotrexate-naive studies.14 The baseline mean age was 47–54 years; female enrolment was 53–85%; the RF+ proportion was 49–100% (see online supplementary table S3). Mean disease duration was 0.1–10 years; baseline DAS28–ESR was 5.5–6.9 and DAS28–CRP ranged from 5.0 to 6.2. Baseline radiographic score and modified total Sharp score (mTSS) showed a wide distribution, with the majority reporting mean scores of 10–20, and others up to 44.77 The feasibility assessment of box plots of distributions of baseline characteristics (see online supplementary figures S15–S26) determined that there were no clinically meaningful differences in baseline characteristics across the studies.

Network meta-analysis results

Patients with inadequate response to methotrexate

The 39 trials from the systematic review were further assessed for the availability of appropriate treatment arms (approved doses), and if none were present, the trial was excluded from the analyses; 23 (59%) had unclear risk of bias, 15 (38%) had low risk of bias and 1 (3%) had a high risk of bias.27 Online supplementary table S4 describes special considerations for studies or treatment arms from certain studies that were not included in the NMA. Four trials were not used in the analyses because they compared two types of TNFi–methotrexate combinations.28 56 58 60 One trial was excluded because none of the endpoints of interest at the time points of interest were reported.59 Another did not evaluate an approved dose for golimumab and was excluded.65 Certain treatment arms from 10 trials evaluated non-approved doses of the TNFis, and hence could not be included in the analyses.30–52 34 43 47 48 53 57 59 61 79–111 Finally, in five trials, data were used until randomisation was truly maintained, up to 6 months in four trials and up to 1 year in another trial; before allowance of additional RA treatments. Thus, 33 primary studies and their follow-up analyses (67 records total) in patients with inadequate response to methotrexate were included in the NMA. The full list of studies included in the NMA and the endpoints available for analysis in each study is shown in online supplementary table S5.
Efficacy

The number of studies used for each analysis along with DIC values for fixed-effects and random-effects models are shown in online supplementary table S6; the network of evidence for the primary endpoint is shown in online supplementary figure S27. Patients with inadequate response to methotrexate were less likely to achieve ACR70 with triple therapy than with TNFi–methotrexate at 6 months in the fixed-effects (OR 0.35, 95% CrI 0.19 to 0.64) and random-effects (OR 0.36, 95% CrI 0.16 to 0.80) models (figure 2; full results in online supplementary table S7). Although the values of the OR for the other efficacy endpoints of ACR20/50, DAS28-ESR remission or low disease activity, DAS28-ESR/CRP remission or low disease activity favoured TNFi–methotrexate, the CrIs extended past 1 and thus a true difference between the two regimens could not be confirmed for these endpoints. Similarly, mean

Figure 1 PRISMA diagram documenting the search and screening process. Articles were identified by searching MEDLINE, EMBASE and Cochrane CENTRAL databases from 1 January 1990 to 9 September 2014; manual bibliography checks of previously published systematic reviews and Cochrane reviews supplemented these searches. Conference abstracts from the American College of Rheumatology Annual Meetings and the Annual European Congresses of Rheumatology in 2012, 2013 and 2014 were used to supplement data not included in the corresponding full-text publications. TNFi, tumour necrosis factor inhibitor.

Fleischmann R, et al. RMD Open 2017;3:e000371. doi:10.1136/rmdopen-2016-000371
Overall, the mean differences between TNFi–methotrexate and triple therapy did not favour either therapy for the radiographic endpoints of mTSS, joint erosion or joint space narrowing. However, differences were

differences for DAS28-ESR and DAS28-ESR/CRP at 6 months did not favour either treatment (figure 3).

Mean differences for radiographic endpoints at 6 months, 1 year and 2 years are shown in figure 3.
observed in the fixed-effects model, but not the random-effects model for mTSS, joint erosion and joint space narrowing that favoured TNFi–methotrexate over triple therapy at 2 years.

Safety
Triple therapy showed lower odds of infection in the random-effects (OR 0.08, 95% CrI 0.00 to 0.57) and fixed-effects (OR 0.08, 95% CrI 0.00 to 0.55) models. For the other safety endpoints of overall adverse events (AEs), discontinuation due to AEs, serious AEs and malignancy, the likelihood of achieving these endpoints were similar between triple therapy and TNFi–methotrexate (figure 4A; full results in online supplementary table S8).

Patient-reported outcomes
TNFi–methotrexate was favoured for mean difference in patient’s general assessment in the fixed-effects, but not random-effects model at 6 months (figure 4B; full results in online supplementary table S7). The two treatments were comparable for Health Assessment Questionnaire-Disease Index and pain scores at 6 months. Comparisons were not available for the other time points.

Methotrexate-naive patients
Further exploration of study design and treatment characteristics was conducted to assess if all available treatment arms or time points could be included in the analyses (see online supplementary table S8). A few considerations were given to certain studies to ensure that only approved doses were included or that study populations at all time points considered for the analysis represented the true randomised population; these are shown in the online supplementary table S9. In three trials,37 92 104 participants were allowed to switch treatments or add additional DMARDs. These studies were not analysed beyond the time point when >20% of participants no longer maintained randomisation. One trial (CONCERTO) evaluated TNFi–methotrexate in all treatment arms and was not included in the analyses.64 112–114 Another study (BeST) was excluded because patients were allowed to receive additional DMARDs in the methotrexate and TNFi–methotrexate arms after 3 months.11 115 116 One trial evaluated TNFi–methotrexate in all treatment arms resulting in it not being feasible to be included in the analyses.112 Thus, 19 primary studies and their associated follow-up analyses were included in the NMA.4571 41 66 26 36 577 117–141 Participants in the TEAR5 trial were assessed for DAS28-ESR at 6 months. Those randomised to the two step-up arms were allowed to add on assigned therapies (etanercept or hydroxychloroquine plus sulfasalazine) if DAS28-ESR was ≥3.2 with methotrexate monotherapy. Data from the first 6 months from the two step-up arms were collapsed to form a methotrexate monotherapy arm in the NMA because no additional treatments were introduced during that time. After 6 months, TEAR was analysed as the

Figure 3  Mean differences in efficacy and radiographic outcomes in triple therapy versus TNFi–methotrexate in patients with inadequate response to methotrexate. CrI, credible interval; CRP, C-reactive protein; DAS28, Disease Activity Score including 28-joint count; ESR, erythrocyte sedimentation rate; FEM, fixed-effects model; mTSS, modified total Sharp score; REM, random-effects model; TNFi, tumour necrosis factor inhibitor.
original four-arm trial. The COmBination of Methotrexate and ETanercept (COMET) trial randomised patients into two arms from baseline to 1 year and to four arms after 1 year until study conclusion at 2 years. Both randomisations occurred at baseline; thus COMET was analysed as a two-arm trial until 1 year. After the 1-year time point, COMET was analysed as a four-arm trial, with arms randomised to switch treatment regimen labelled as ‘switch 1’ (combination etanercept plus methotrexate therapy for the first 52 weeks; after 52 weeks patients continued methotrexate, and etanercept was switched to placebo) and ‘switch 2’ (methotrexate monotherapy plus placebo for the first 52 weeks; after 52 weeks patients continued to receive methotrexate, and placebo was switched to etanercept).

The full list of studies of methotrexate-naive patients included in the NMA and the endpoints available for analysis are shown in online supplementary table S10.

### Efficacy

The number of studies used in each analysis along with DIC values for fixed-effects and random-effects models are shown in online supplementary table S11; the
network of evidence for the analysis of the primary endpoint is shown in online supplementary figure S28. Full results of the NMA are shown in online supplementary table S12 and figure S29; OR values <1 indicate a better performance for TNFi–methotrexate over triple therapy. For the primary endpoint, ACR70 at 6 months in methotrexate-naive patients, the OR in the fixed-effects model was 0.76 (95% CrI 0.36 to 1.50); for the random-effects model, the OR was 0.77 (95% CrI 0.31 to 1.76). Achievement of ACR70 at 2 years was more likely in patients treated with TNFi–methotrexate compared with triple therapy in the fixed-effects model (OR, 0.44, 95% CrI 0.22 to 0.82) but not the random-effects model (OR 0.43, 95% CrI 0.14 to 1.28). Similarly, the likelihood of no radiographic progression was more likely in patients treated with TNFi–methotrexate compared with triple therapy in the fixed-effects model (OR 0.48, 95% CrI 0.25 to 0.9) but not the random-effects model (OR 0.47, 95% CrI 0.15 to 1.41). No differences were indicated based on ORs for ACR50 or ACR20 at 6 months or 2 years, or in DAS28-ESR remission at 2 years. Mean differences between TNFi–methotrexate and triple therapy did not favour either therapy in either model for the efficacy endpoints for DAS28-ESR/CRP or DAS28-ESR at 3 months, 6 months, 1 year, or 2 years.

Mean differences between TNFi–methotrexate and triple therapy for the radiographic endpoints of change in joint space narrowing, change in joint erosion or change in mTSS at 2 years did not favour either therapy in either model. (see online supplementary figure S30). No comparisons were available for these endpoints at other time points.

Safety
The ORs showed no difference in the odds of discontinuations due to AEs, overall AEs, serious infections and aspartate aminotransferase elevation between TNFi–methotrexate and triple therapy in patients naive to methotrexate (see online supplementary table S13 and figure S31A).

Patient-reported outcomes
Comparisons were available for the Health Assessment Questionnaire-Disability Index and patient general assessment (PAG) at 2 years; no difference in likelihood of achieving these outcomes was observed between TNFi–methotrexate and triple therapy (see online supplementary table S12 and figure S31B).

Sensitivity analysis
The sensitivity analysis of DAS28-ESR remission at 2 years using non-responders data from the COMET trial gave similar results for the comparison of triple therapy versus TNFi–methotrexate. The TEAR trial reported non-responder imputation and completer data for DAS28-ESR change from baseline at 3 months, 6 months, 1 year and 2 years. The results of the sensitivity analysis were consistent with the direction and magnitude of our main results, with a few exceptions, including mean change in DAS28-ESR at 3 months and 2 years when non-responders imputation data were used. At 3 months, the fixed-effects model result using TEAR last observation carried forward data was 0.21 (95% CrI −0.03 to 0.46), whereas in the sensitivity analysis using non-responders imputation data, the resulting mean difference from the fixed-effects model between TNFi–methotrexate and triple therapy was 0.30 (95% CrI 0.06 to 0.54). Although at 2 years, the observed result was similar to the results obtained from the last observation carried forward analysis, there was a change in the directionality of the relative treatment effect, with a trend of TNFi–methotrexate performing better in the sensitivity analysis using non-responders imputation data.

DISCUSSION
This is the first study to provide a systematic, qualitative and quantitative review of the published literature across critical efficacy, radiographic, safety and PRO endpoints in patients with RA receiving TNFi–methotrexate or triple therapy. This NMA showed that in methotrexate-naive patients there was no difference in the likelihood of achieving clinical efficacy endpoints between triple therapy and TNFi–methotrexate. Although most endpoints favoured TNFi–methotrexate in terms of OR directionality, such a result is not likely to be clinically relevant. In patients with inadequate response to methotrexate, the NMA shows better outcomes for patients treated with TNFi–methotrexate versus triple therapy with respect to the primary endpoint of ACR70 at 6 months; other endpoints were favourable in terms of directionality of the OR, but the limits of the CrIs indicated no clear difference for either therapy. In patients with inadequate response to methotrexate, triple therapy had 65% lower odds than TNFi–methotrexate in achieving ACR70 at 6 months. Trends showing benefits of TNFi–methotrexate were observed across the majority of endpoints. Taken together, these results indicate that the two treatment strategies are comparable, although TNFi–methotrexate may be associated with deeper responses.

Our results suggest that the addition of a TNFi to methotrexate after inadequate response to methotrexate could result in better outcomes compared with the addition of sulfasalazine and hydroxychloroquine, chiefly with ACR70 at 6 months. Our finding is therefore applicable to most patients who do not achieve a good response with methotrexate monotherapy. It should be noted that current EULAR guidelines recommend that patients without unfavourable prognosis fail at least two csDMARDs before proceeding to biologic therapy; unfortunately, this could not be examined in this analysis. Nevertheless, our results support the current ACR guidelines and the current recommendation of adding TNFi to methotrexate in patients with an unfavourable prognosis per EULAR.
directionality favoured TNFi–methotrexate over triple therapy in this population at 1 and 2 years, CrIs extended past 1, indicating no increased likelihood of response for either therapy; however, comparison of these time points were limited by the number of studies and data points available for analysis. Therefore, the durability of the difference between TNFi–methotrexate and triple therapy in patients with inadequate response to methotrexate is uncertain. Our results suggest that patients given combination therapy as first-line treatment benefit comparably from triple therapy and TNFi–methotrexate. Results of recent studies suggest that in patients naive to methotrexate, outcomes at 2 years are similar among patients treated with methotrexate monotherapy and ‘step-up’ to combination therapy and those treated early with TNFi–methotrexate combination therapy or triple therapy.5 16 Starting treatment with methotrexate monotherapy is recommended by EULAR and the ACR1 2 and is the approach most often used in clinical practice. Importantly, initial treatment with a biologic agent would not be reimbursed in most countries and is not necessary in all patients; therefore, although of interest, these findings would not be applicable to most patients with early RA naive to methotrexate. It is noteworthy that the present analysis was designed and conducted before the most recent recommendations, thus it was deemed important to the investigators to include these data. It should also be noted that the use of corticosteroids in some patients is a potential confounder to these results but due to randomisation, it is likely that steroids were used equally in all treatment groups within any trial.

In patients with inadequate response to methotrexate, the majority of safety outcomes were similar between the two treatment regimens; however, an increased risk of infection was noted for TNFi–methotrexate. Safety outcomes were also similar between the treatment regimens in patients naive to methotrexate. Improvements in PGA and pain scores were greater for patients treated with TNFi–methotrexate compared with triple therapy in those with inadequate response to methotrexate (random-effects model only); negligible differences between the two regimens were observed in PGA scores in the methotrexate-naive population.

In this NMA, we present the results from fixed-effects and random-effects models. Typically, random-effects models are preferred because it is generally accepted that baseline characteristics and potential effect modifiers do not have equal distribution across trials, unlike fixed-effects models, which assume a common treatment effect size across trials comparing the same interventions.142 In our limited sample of studies, we found the baseline clinical values across the trials considered for the NMA to be clinically uniform. Beyond examining box plots to assess the distribution of baseline characteristics, an informal graphical check of the treatment effect modifiers of clinically important baseline values was performed. As available data were sparse, we could not come to a conclusive finding of any treatment effect modifier among the available baseline values. The fixed-effects model results are most applicable to our data set because we could not ascertain any systematic differences between the patient populations included, and we compared only two or fewer studies per intervention in each network.

Advantages of NMA over traditional meta-analyses include the ability to compare directly and indirectly.17 This NMA was designed using best practice guidelines to identify all RCTs available; all available literature was considered. Stratifying the base analysis population by prior exposure to methotrexate alleviates concerns over the prior treatment and response differences across the studies. The combinations of TNFi–methotrexate were prespecified and included only approved doses of TNFi for the treatment of RA; triple therapy was specifically a combination of methotrexate, hydroxychloroquine and sulfasalazine. All available efficacy, radiographic, PRO and safety endpoints were assessed to provide an overall understanding of the relative treatment estimates for the comparison of triple therapy to TNFi–methotrexate.

Limitations of this analysis were that few studies with a common comparator (methotrexate monotherapy) were available; in particular, there was a lack of methotrexate monotherapy arms in studies that evaluated triple therapy. Therefore, results were driven by the few studies that had head-to-head comparison between triple therapy and TNFi–methotrexate and should be interpreted cautiously. We also considered all doses of methotrexate as equal between the treatment arms in the network, which is a potential confounder to our results. Also, certain studies were not included because their endpoints differed from other studies or included patients who received other therapies or used definitions of methotrexate-naive that included patients who had received methotrexate. Furthermore, any negative results not available to the searched databases because of publication bias are excluded from our analysis. Finally, not all endpoints used for inclusion in the study could be analysed in the NMA; for safety, the only specific AEs that could be analysed in the NMA were infection, malignancy and aspartate aminotransferase elevation.

In conclusion, in patients who were naive to methotrexate treatment, neither triple therapy nor TNFi–methotrexate showed an increased likelihood of achieving ACR70 at 6 months; at the group level, these two treatment strategies appear comparable. The majority of secondary endpoints favoured TNFi–methotrexate in terms of OR directionality, although the limits of the CrIs indicated no clear likelihood of better response with either therapy. TNFi–methotrexate showed increased odds of achieving ACR70 at 6 months over triple therapy, suggesting a possible deeper response with TNFi–methotrexate over triple therapy. These conclusions are in line with the recent ACR guidelines and
the EULAR recommendations for the treatment of RA in patients with poor prognostic markers. In patients without poor prognostic markers, it would be reasonable to use either therapy combination.

Author affiliations
1Department of Internal Medicine, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, Texas, USA
2Oxford Outcomes, ICON plc, Morristown, New Jersey, USA
3Department of Medicine, Karolinska Institutet, Stockholm, Sweden
4Ampen Inc., Thousand Oaks, California, USA
5Novartis Pharmaceuticals, East Hanover, New Jersey, USA
6Doctors’ Hospital of Michigan, Pontiac, Michigan, USA
7Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
8Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada

Acknowledgements
Medical writing support was provided by Dikran Toroser, PhD, CMPP (Ampen) and Miranda Tradewell, PhD, and Rick Davis, MS (Complete Healthcare Communications, LLC, funded by Ampen). Manpreet Sidhu, PhD, and Neil Hawkins, PhD, reviewed and provided input on the study protocol, input on analyses approaches and assumptions, and review of analyses results and interpretation.

Contributors
All authors meet the criteria for authorship, participated in the writing and/or critical revision of the manuscript, and have seen and approved the submitted version. JC, DC, RF, KN, JP, DHT, VT, CVv and GW were involved in data acquisition. JC, DC, RF, KN, JP, VT, SU and RVv analysed the data. JC, DC, RF and JP drafted the manuscript. All authors interpreted the results and critically revised the manuscript.

Funding
Ampen Inc.

Competing interests
RF has received grants and non-financial support from Ampen. VT, SU and KN are employees of ICON plc, which received grants and consulting fees from Ampen. RVv has received grants from Abbvie, Apen, Bristol-Morleys Squibb, GlaxoSmithKline, Pfizer, Roche and Union Chimique Belge, and personal fees from Abbvie, Amgen, Bientote, Bristol-Morleys Squibb, Celgene, Crescendo, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Roche, Union Chimique Belge and Vertex. DHT, JC and DC are employees and stockholders of Amgen. JP received grants from Apen and received consulting fees from Abbvie, Amgen, Bristol-Morleys Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche and Union Chimique Belge. GW had nothing to disclose.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data sharing statement
No additional data are available.

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
1. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 2016;68:1–26.
2. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:482–509.
3. van Vollenhoven RF, Erneastm S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374:459–66.
4. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2006;372:375–82.
5. Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64:2924–35.
6. van der Heijde D, Klareskog L, Wajdula J, et al. Sustained halting of joint damage with combination etanercept and methotrexate: 3-year results from the TEMPO trial. Ann Rheum Dis 2006;65:509.
7. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
8. de Jong PH, Hazes JM, Hak-VK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy: 1-year data of the iREACH trial. Ann Rheum Dis 2014;73:1331–9.
9. Keystone EC, Breedveld FC, van der Heijde D, et al. Long-term effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol 2014;41:1–14.
10. Rantalaiho V, Korpela M, Laasonen L, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Rheum 2010;62:172–202.
11. Goekoop-Ruiterman YP, van Beers-Bouwstra JK, Allardt CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2008;58:S126–35.
12. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702–10.
13. Nam JH, Ramiro S, Jaujou-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:15–28.
14. O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287–91.
15. Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712–20.
16. O’Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum 2013;65:1985–94.
17. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ 2013;346:f1410. doi:10.1136/bmj.f1410.
18. Buckley F, Finckh A, Huizinga TW, et al. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm 2015;21:409–23.
19. Lee YH, Bae SC, Song GG. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int 2015;35:1865–74.
20. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Syst Rev 2012;1:41.
21. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
22. Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ 2011;343:d5928.
23. The Cochrane Collaborations. Cochrane Handbook for Systematic Reviews of Interventions. http://handbook.cochrane.org/front_page.htm (accessed 23 Sep 2015).

24. Chen D, Chou SJ, Hsieh TY, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc 2009;108:310–19.

25. Abe T, Takeuchi T, Miyasaka N, et al. A multicenter, double-blind, randomized, placebo-controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 2006;33:37–44.

26. Choy E, McKenna F, Vencovsky J, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford) 2012;51:1226–34.

27. Durez P, Nzesseu Toukap A, Lauwerys BR, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methyprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis 2004;63:1069–74.

28. Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007;66:893–9.

29. Kameda H, Ueki Y, Saito K, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol 2010;20:531–7.

30. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964–75.

31. Kavanagh A, Cao CL, McCoy WJ, et al. Chimeric anti-tumor necrosis factor-alpha monocular antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841–50.

32. Keystone E, Heijde DV, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;59:391–9.

33. Keystone EC, Genovese MC, Klareskog L, et al. GO-FORWARD Study. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 2009;68:789–96.

34. Keystone EC, Kavanagh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11.

35. Kim HY, Hsu PN, Barba M, et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. Int J Rheum Dis 2015;18:99–106.

36. Kim HY, Lee SK, Song YW, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean patients with active rheumatoid arthritis: the APPEAL trial. Int J Rheum Dis 2015;18:99–106.

37. Kim J, Ryu H, Yoo DH, et al. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. J Korean Med Sci 2013;28:1716–22.

38. Kramer J, Rigden C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917–28.

39. Lan JL, Chou SJ, Chen DY, et al. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc 2004;103:618–23.

40. Machado DA, Guzman RM, Xavier RM, et al. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. J Clin Rheumatol 2014;20:25–33.

41. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in European patients with rheumatoid arthritis who had an inadequate response to conventional therapy: a randomized study. Lancet 1999;354:1932–9.

42. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.

43. O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307–18.

44. Schiff M, Keiserman M, Coddin C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-center, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2006;67:1086–103.

45. Smolen JS, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPIID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797–804.

46. Smolen JS, Shang J, Li EK, et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis—a randomized trial. J Rheumatol 2012;39:2267–75.

47. Tanaka C, Shiozawa K, Hashiramoto A, et al. A study on the selection of DMARDS for the combination therapy with adalimumab. Kobe J Med Sci 2012;58:37–42.

48. Tanaka Y, Harigai M, Takeuchi T, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 2012;71:1817–24.

49. Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004;50:1107–16.

50. van Riel PL, Taggart AJ, Sny J, et al. Add Enbrel or Replace Methotrexate Study Investigators. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006;65:1478–83.

51. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508–19.

52. Weinblatt ME, Biohl CM III, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013;72:381–9.

53. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35–45.

54. Weinblatt ME, Schiff M, Valetine R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomised study. Arthritis Rheum 2013;65:28–38.

55. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253–9.

56. Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, drug-controlled study. Arthritis Rheum 2008;58:1921–30.

57. Yamamoto K, Takeuchi T, Yamakana H, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheumatol 2014;24:552–60.

58. Yoo DH, Hycja P, Miranda P, et al. Randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613–20.
Rheumatoid arthritis

59. Zhang FC, Hou Y, Huang F, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol 2006;9:127–30.

60. Takeuchi T, Miyasaka N, Inoue K, et al. Impact of trough serum level on radiographic and clinical outcomes in infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009;19:478–87.

61. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075–86.

62. Takeuchi T, Yamaoka H, Ishiguro N, et al. Adalimumab, a human anti-tnf monoclonal antibody, outcome studyption for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL study. Ann Rheum Dis 2007;66:538–43.

63. Horslev-Petersen K, Hettland M, Junker P, et al. OPERA Study-Group. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 2014;73:654–61.

64. Burmester G, Kivitz A, Kupper H, et al. Efficacy, pharmacokinetics, and safety of etanercept at various doses of methotrexate in combination with adalimumab: results from the CONCERTO trial [abstract]. Ann Rheum Dis 2013;72(Suppl 1):A72–A73.

65. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 52 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844–50.

66. Kavanagh A, Fleischmann R, Emery P, et al. Efficacy of addition, or continuation of adalimumab in patients who did not achieve stable low disease activity with methotrexate or adalimumab plus methotrexate in the optima study. Ann Rheum Dis 2013;71:511–12.

67. Soubrier M, Puéchal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 2009;48:1429–34.

68. Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor alpha adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467–74.

69. Iannone F, La Montagna G, Bagnato G, et al. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: results of a randomized clinical trial. J Rheumatol 2014;41:286–92.

70. Klareskog L, van der Heijde D, De Jager J, et al. Clinical outcomes of a double-blind study of etanercept and methotrexate, alone and combined, in patients with active rheumatoid arthritis (TEMPO trial), year 2 results. Ann Rheum Dis 2004;63:OP0003.

71. Yamaoka H, Yamamoto K, Takeuchi T, et al. Improved functional performance, pain, and quality of life with certolizumab pegol in Japanese rheumatoid arthritis patients without methotrexate co-administration: results from the Hikari study. Ann Rheum Dis 2013;71:664.

72. Van Vollenhoven RF, Wallenstein G, Lee EB, et al. Effects of oficitinib (CP-890,550), an oral Janus kinase inhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis. Ann Rheum Dis 2013;71:206.

73. Tanaka Y, Yamamoto K, Takeuchi T, et al. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from a open-label extension of the J-RAPID study. Mod Rheumatol 2014;24:734–43.

74. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active rheumatoid arthritis (GEMINI II): 2-year results. Ann Rheum Dis 2014;73:149–57.

75. Kameda H, Kanke K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: week 52 results from the JESMR study. J Rheumatol 2011;38:1119–26.

76. Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the Rapid I trial. Rheumatology (Oxford) 2012;51:1628–39.

77. Strand V, Kramer P, Burmester GR, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the TEMPO 1 randomized controlled trial. Arthritis Res Ther 2009;11:R70.

78. Conaghan PG, Emery P, Ostergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968–74.

79. Conaghan PG, Emery P, Ostergaard M, et al. Assessment of inflammation and damage by MRI in established RA patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Arthritis Res Ther 2004;6:363:R75–R71.

80. Genovese MC, Han C, Keystone EC, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 2012;39:1185–91.

81. Genovese MC, Keystone EC, Hsia EC, et al. Impact of golimumab on physical function, health-related quality of life, productivity and employment in rheumatoid arthritis patients: week 52 results from the GO-FORWARD study. Int J Rheum Dis 2010;13:88.

82. Keystone EC, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol 2013;40:1097–103.

83. Rubbert A, Keystone E, Genovese M, et al. Golimumab administered subcutaneously every 4 weeks in active rheumatoid arthritis despite methotrexate: week 24 results of Go-Foward Study. Rheumatology (Oxford) 2013;52:192.

84. Bae SC, Gun SC, Mok CC, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskel Disord 2013;14:13.

85. Atsumi T, Yamamoto K, Takeuchi T, et al. The first early rheumatoid arthritis, certolizumab pegol, multicenter, double-blind, randomized, parallel-group study: C-Opea, in patients fulfilling the 2010 ACR/EULAR classification criteria, demonstrates inhibition of joint damage progression. Ann Rheum Dis 2014;73:484.

86. Bingham CO III, Weinblatt ME, Mendelsohn A, et al. Predictors of significant disease activity score-28 (using C-reactive protein) remission achieved with intravenous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results of...
the phase iii, multicentre, double-blind, placebo-controlled trial. *Rheumatology (Oxford)* 2013;52:82–13.

95. Bingham CO III, Weinblatt M, Han C, et al. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 26-week results of a placebo-controlled trial of the phase III, multicentre, double-blind, placebo-controlled trial. *Arthritis Rheum* 2012;64:S558.

96. Bingham CO III, Weinblatt M, Mendelsohn AM, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum* 2004;50:1051–65.

97. Rezaei H, Saevarsdottir S, Geborek P, et al. Evaluation of hand bone loss by digital X-ray radiography: a comparison to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial. *BMC Musculoskel Disord* 2013;14:79.

98. Schiffl M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPEL trial. *Ann Rheum Dis* 2014;73:86–94.

99. Smolen J, Keystone E, Schiffl M, et al. Sustained long-term efficacy of certolizumab pegol plus methotrexate in the treatment of rheumatoid arthritis: 2-year analysis of the Rapid 1 study. *Rheumatology* 2009;48:i5–6.

100. Strand V, Smolen JS, van Vollenhoven RF, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: 2-year results of the RAPID 2 trial. *Ann Rheum Dis* 2011;70:996–1002.

101. Tanaka Y, Harigai M, Takeuchi T, et al. Predictors of significant disease activity score-28 (using C-reactive protein) remission achieved with intravenous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results of the phase 3, multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2014;66:1076–77.

102. Tanaka Y, Harigai M, Takeuchi T, et al. Methotrexate dose has minimal impact on methotrexate-related toxicity in patients with early rheumatoid arthritis treated in combination with adalimumab-results of the CONCERTO trial [abstract]. *Ann Rheum Dis* 2013;72(Suppl 10):A246.

103. Strande V, Smolen JS, McInnes IB, et al. Efficacy and safety of mamulizumab against subjects with rheumatoid arthritis. *Ann Rheum Dis* 2013;72:1445–52.

104. Fleischmann RM, Kivitz AJ, Van Vollenhoven RF, et al. No differences in patient-reported outcomes by methotrexate dose among early rheumatoid arthritis patients treated concomitantly with adalimumab: results from the CONCERTO trial [abstract]. *Arthritis Rheum* 2013;65:S574–55.

105. Goekoop-Ruyten MP, De Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2007;146:406–15.

106. van der Heijde DM, St Clair EW, et al. Radiographic and safety results, including evaluation of remission rates acquired by adding adalimumab to methotrexate and intra-articular glucocorticoids in patients with early rheumatoid arthritis: 1-year results of the investigator-initiated, randomized, double-blinded, placebo-controlled trial. *Scand J Rheumatol* 2012;41:17–18.

107. Horslev-Petersen K, Hetland ML, Junker P, et al. Addition of infliximab to methotrexate and intra-articular glucocorticoids increases remission rates at one year in early, DMARD-naive patients with rheumatoid arthritis: an investigator-initiated randomized, controlled, double-blind study (abstract). *Arthritis Rheum* 2011;65:S394–395.

108. Horslev-Petersen K, Hetland ML, Junker P, et al. Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab; year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis (OPERA). *Arthritis Rheum* 2013;65:S1148.

109. Horslev-Petersen K, Hetland ML, Junker P, et al. Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoids cannot be maintained after withdrawal of adalimumab. *Ann Rheum Dis* 2011;66:1697.

110. Detert J, Bastian H, Listing J, et al. Efficacy of an induction therapy with adalimumab plus methotrexate or monotherapy in recent onset rheumatoid arthritis—an investigator initiated randomised controlled trial [abstract]. *Ann Rheum Dis* 2013;72:A236.

111. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate or monotherapy in recent onset rheumatoid arthritis (RA)—an investigator initiated randomized controlled trial. *Ann Rheum Dis* 2013;71:102–3.

112. Kavanaugh A, Emery P, Fleischmann R, et al. Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial. *Arthritis Rheum* 2011;63:1699.

113. Kavanaugh A, Fleischmann R, Emery P, et al. Clinical and functional improvements in early RA following treatment with adalimumab plus methotrexate compared with methotrexate monotherapy: 26-week results of the Optima trial. *Arthritis Rheum* 2010;62:1791.

114. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate versus methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. *Ann Rheum Dis* 2013;72:64–71.

115. Smolen JS, Fleischmann RM, Emery P, et al. Treating rheumatoid arthritis to target: outcomes and predictors in early rheumatoid arthritis patients treated with adalimumab plus methotrexate, methotrexate alone or methotrexate plus subsequent adalimumab. *Rheumatology (Oxford)* 2012;51:114–15.

116. Emery P, Kavanagh A, Smolen JS, et al. Combination therapy with adalimumab-methotrexate significantly improved work ability, physical function, fatigue, and other patient-reported outcomes in early rheumatoid arthritis: results from a 26-week analysis. *Arthritis Rheum* 2011;63:2189.
128. Kimel M, Cifaldi M, Chen N, et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008;35:206–15.

129. Strand V, Rentz AM, Cifaldi MA, et al. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol 2012;39:63–72.

130. Emery P, Breedveld F, van der Heijde D, et al., Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010;62:674–82.

131. Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010;69:222–5.

132. Anis A, Zhang W, Emery P, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford) 2009;48:1283–9.

133. van der Heijde D, Klareskog L, Boers M, et al., TEMPO Investigators. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005;64:1582–7.

134. van der Heijde D, Klareskog L, Rodríguez-Valverde V, et al., TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063–74.

135. van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis 2006;65:328–34.

136. Emery P, Fleischmann RM, Doyle MK, et al. Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res 2013;65:1732–42.

137. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, in methotrexate-naive active rheumatoid arthritis (Go-Before study). Rheumatology 2009;48:93.

138. Østergaard M, Emery P, Conaghan PG, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum 2011;63:3712–22.

139. Haugeberg G, Conaghan PG, Quinn M, et al. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2009;68:1898–901.

140. Valleala H, Kautiainen H, Mottonen T, et al. Bone mineral density in patients with recent onset, active rheumatoid arthritis: two-year data of the NEO-RACo study. Arthritis Rheum 2009;60:1008.

141. Moreland LW, O’Dell JR, Paulus HE, et al. Two-year radiographic results from the TEAR trial. Arthritis Rheum 2010;62:1368.

142. Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform healthcare decision-making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014;17:157–73.